January 6, 2026 did not come with fireworks, but it landed like a pressure change. Utah approved something no other state has put its name on. Not a pilot dressed up as innovation. Not a PR rehearsal. A real regulatory partnership that lets an AI system legally renew prescription medications for real patients. Healthcare rarely moves this quietly when something big breaks. This one did.
The company is Doctronic, Inc., founded in New York City in May 2024, and backed first by Union Square Ventures before Lightspeed Venture Partners led a $20M Series A just four months after seed. Faraz Fatemi did not preempt that round for vibes. He did it because the product was already behaving like infrastructure. When Utah’s Department of Commerce looked for an AI partner willing to be measured instead of marketed, Doctronic raised its hand.
Through the Office of Artificial Intelligence Policy, Executive Director Margaret Woolley Busse and Senate Majority Leader Kirk Cullimore approved a 12 month regulatory sandbox allowing Doctronic’s autonomous AI to renew routine prescriptions for #chronic conditions. Not controlled substances. Not #ADHD meds. Not injectables. 190 common medications that represent the quiet majority of healthcare touchpoints and nearly 80% of prescription activity.
The process is clinical, not theatrical. Patients verify they are physically in Utah, confirm identity, complete the same intake a physician would run, and the AI evaluates the renewal. When certainty drops, a licensed physician steps in. The first 250 prescriptions in each medication class are reviewed by doctors before autonomy scales. Malpractice insurance is live. HIPAA compliance is explicit. Every outcome is tracked.
Doctronic Co-Founder and Co-CEO Matt Pavelle brings 25+ years of consumer systems thinking, including scaling Moda Operandi. He paired that instinct with Dr. Adam Oskowitz, a UCSF vascular surgeon who has spent decades watching medication non compliance turn manageable disease into avoidable catastrophe. Together they built a system that matched physician treatment plans in 99.2% of 500 real urgent care cases, published and peer reviewed.
The price is $4 per renewal for now. Less than parking. Less than a co pay. Less than delay. The real signal is not cost. It is precedent. The FDA deferred. The state stepped forward. The sandbox is no longer theory. It is operational.
